Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Phase 3 Trial
Sort By
Newest First
1 / 1
1 / 1
Clinical Trials
GBT Announces Efficacy Data from All Patients Enrolled in Phase 3 Study Sustained Improvements in Hemoglobin with Voxelotor
GBT
PR-M06-19-NI-025
Jun 18, 2019
Oncology
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
Eli Lilly and Company
PR-M01-19-NI-067
Jan 23, 2019
PR-M10-18-NI-081
BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
BiondVax
Investment
Oct 24, 2018
Phase III Trial
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib
Takeda
PR-M07-18-NI-094
Jul 27, 2018
Phase III Trial
Endoscopy Publishes the Dayb Phase III Trial for Plenvu®(Ner1006), the First One Litre Peg Bowel Preparation[i]
Norgine
PR-M07-18-NI-089
Jul 26, 2018
Clinical Data
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In
Array BioPharma
PR-M06-18-NI-086
Jun 26, 2018
Clinical Trials
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting
Sage Therapeutics
PR-M06-18-NI-060
Jun 18, 2018
Clinical Data
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant
Allergan, plc
PR-M06-18-NI-051
Jun 14, 2018
Clinical Data
NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
Northwest Biotherapeutics
PR-M06-18-NI-009
Jun 04, 2018
Trial Results
IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
AbbVie
PR-M05-18-NI-102
May 28, 2018
Phase 3 Trial
LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Pfizer
PR-M05-18-NI-077
May 21, 2018
